Patent · US Active

Method for the in vitro prediction of the probability of a patient developing severe dengue, based on a blood sample

US10823732B2 · kind B2 · utility

0Cited by
0References
9Claims
0Family size

Assignee

Inventor

Key dates

Filing dateDec 22, 2017
Grant dateNov 3, 2020
Priority date
Expiry dateJun 8, 2038

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

A kit for in vitro prediction of severe dengue includes a binding partner specific for leucine-rich alpha-2 glycoprotein, a binding partner specific for vitamin D-binding protein, and a binding partner specific for ferritin. The kit may further include at least one binding partner specific for a dengue virus protein wherein the dengue virus protein is the NS1 protein, the envelope protein, or the prM protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.